724 results on '"Hurle, Rodolfo"'
Search Results
152. PD41-02 A NEW PROPOSAL FOR T1, HIGH GRADE (HG) BLADDER CANCER (BCA) MICRO-STAGING DEFINITION
153. MP26-04 SAFETY, EFFICACY AND 12-MONTHS RECURRENCE RATE OF LASER VS. ELECTRICAL EN BLOC RESECTION OF UROTHELIUM CARCINOMA OF THE BLADDER: RESULTS OF THE EBRUC TRIAL
154. MP26-05 ACTIVE SURVEILLANCE PROGRAM IN RECURRENT NMIBC
155. Inflammatory markers and Type 2 diabetes mellitus as prognostic risk factors in low‐risk bladder cancer.
156. Combination of AST to ALT and neutrophils to lymphocytes ratios as predictors of locally advanced disease in patients with bladder cancer subjected to radical cystectomy: Results from a single-institutional series
157. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy
158. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy
159. Editorial Comment
160. Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients
161. IMPACT OF A DEDICATED TEACHING PROGRAM ON QUALITY OUTCOMES OF WHITE LIGHT TURBT: MP65-02
162. DEVELOPMENT AND EXTERNAL VALIDATION OF NOMOGRAMS PREDICTING DISEASE-FREE AND CANCER SPECIFIC SURVIVAL AFTER RADICAL CYSTETCOMY: MP55-11
163. PROSTATE CANCER URINE DETECTION THROUGH HIGHLY-TRAINED DOGS’ OLFACTORY SYSTEM: A REAL CLINICAL OPPORTUNITY: PD19-01
164. Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology
165. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis
166. Combination of AST to ALT and neutrophils to lymphocytes ratios as predictors of locally advanced disease in patients with bladder cancer subjected to radical cystectomy: Results from a single-institutional series.
167. Oncology and complications
168. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure
169. Impact of anti-androgenic therapies on COVID-19: an observational study in male population from a COVID-19 regional centre of Lombardy (Italy)
170. Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer
171. Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer
172. The Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage
173. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study
174. Overview of the italian experience in surgical management of bladder cancer during first month of COVID-19 pandemic
175. The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer
176. Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective Trial.
177. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer
178. Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
179. Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging
180. Surgical Management of Bladder Cancer During First Month of COVID-19 Outbreak: Lessons Learned Across Italy
181. Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma.
182. The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication.
183. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor
184. Active surveillance for recurrent low-grade non-muscle-invasive bladder cancer: Can we take any advantage from the COVID-19 crisis?
185. PD12-04 ONCOLOGICAL LONG-TERM SAFETY AND PATHOLOGICAL OUTCOME EVALUATION FOR PATIENTS UNDER ACTIVE SURVEILLANCE FOR RECURRENT LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER
186. PD12-01 ONCOFID-P-B FOR THE TREATMENT OF BCG UNRESPONSIVE CARCINOMA IN SITU (CIS) OF BLADDER
187. PD12-06 HEAD-TO-HEAD COMPARISON BETWEEN MICRO-ULTRASOUND AND MRI IN THE DIFFERENTIATION BETWEEN MUSCLE-INVASIVE AND NON-MUSCLE INVASIVE BLADDER CANCER
188. MP01-07 MITOMYCIN C SENSITIVE TUMOR CELLS GENERATE AN INFLAMMATORY SECRETOME CAPABLE OF INDUCING ANTI-TUMOR IMMUNE RESPONSES
189. PD12-11 LONG-TERM FOLLOW-UP IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER “EN-BLOC” RESECTION
190. MP55-07 PREDICTIVE AND PROGNOSTIC ROLE OF A SIMPLE IMMUNO-PHENOTYPICAL SCORE IN CLINICAL MANAGEMENT OF PATIENTS WITH PT2 INVASIVE UROTHELIAL CARCINOMA
191. MP15-16 LASER LITHOTRIPTER SETTINGS ACCORDING TO ENDOSCOPIC VIEW: HOW CAN WE OPTIMISE THE OUTCOME? A SIMPLE WAY TO OPTIMISE THE TREATMENT STRATEGY
192. MP23-05 THE UTILITY OF MICRO-ULTRASOUND IN PATIENTS UNDER ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: A PRIAS STUDY EXTENSION
193. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?
194. Characterization of the urinary microbiota in bladder cancer patients.
195. Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder: Results of European multicenter phase I study at the end of 12- consecutive weeks intensive course.
196. TMPRSS2: ERG expression in prostate cancer—Imaging and clinicopathological correlations.
197. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
198. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy.
199. Impact on Sexual Function of Holmium Laser Enucleation Versus Transurethral Resection of the Prostate: Results of a Prospective, 2-Center, Randomized Trial
200. MP74-08 [68GA]PSMA PET/CT VS. MPMRI IN PATIENTS WITH SUSPICION OF PROSTATE CANCER AND PREVIOUS NEGATIVE BIOPSY: RESULTS OF THE PROSPET-BX TRIAL.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.